Dipeptidyl Peptidase 4 Inhibitors vs Metformin for New-onset Dementia: A Propensity Score-matched Cohort Study
Main finding · All-cause dementiaResult — go to the resultHazard ratio 0.63 95% CI 0.45–0.89Authors' conclusion
In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.
Study context
- Population
- Individuals with T2D over 40 years old, new users of DPP4 inhibitors or metformin, Chinese Renal Disease Data System database, 2009–20201:1 matched
- Exposure
- DPP-4i vs metformin
- DPP4 inhibitorsn = 3,626
- Outcome
- All-cause dementia
Methodological details1:1 propensity score matching, real-world, Kaplan-Meier and Cox regression; Fine and Gray model for competing risk of death
- 1:1 propensity score matching
- Real-world
- Kaplan-Meier and Cox regression; Fine and Gray model for competing risk of death
Main finding
As reported in the abstract
Hazard ratio
0.63
95% CI 0.45–0.89
DPP4 inhibitorsvs Metformin
HR 0.63 (95% CI 0.45–0.89)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Dementia, subgroup: initiated therapy at age ≥60 years | 0.69 (0.48–0.98) | |
| Dementia, subgroup: without baseline macrovascular complications | 0.62 (0.41–0.96) | |
| Dementia, subgroup: without baseline microvascular complications | 0.67 (0.47–0.98) | |
| 0.512Hazard ratio (log scale) |
Original publication
Dipeptidyl Peptidase 4 Inhibitors vs Metformin for New-onset Dementia: A Propensity Score-matched Cohort Study. J Clin Endocrinol Metab. Published 23 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →